Finding the Optimal Dose of Regorafenib in Colorectal Cancer
John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.
John H. Strickler, MD, medical oncologist, Duke Cancer Center, Duke Health, discusses dosing of regorafenib (Stivarga) in colorectal cancer.
Treatment with regorafenib in patients with colorectal cancer often involves dose escalations. The purpose for escalating the dose of this drug is to ensure that patients receive a dose that provides the best quality of life.
Efficacy is typically not sacrificed when patients are given a lower dose of regorafenib and are gradually escalated to a higher dose, says Strickler. In addition, there is no data to suggest that a higher dose of regorafenib improves efficacy. Strickler recommends focusing on the tolerability of the agent when deciding on escalation or even de-escalation, if needed.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
